09:31 AM EDT, 07/30/2024 (MT Newswires) -- Day One Biopharmaceuticals ( DAWN ) posted a Q2 net loss Tuesday of $0.05 per diluted share, narrowing from a loss of $0.61 per share a year earlier.

Analysts polled by Capital IQ expected a loss of $0.75.

Net product revenue for the quarter ended June 30 was $8.2 million. No revenue was reported for a year earlier.

Analysts surveyed by Capital IQ expected $910,000.

As of June 30, the clinical-stage biopharmaceutical company said it had $361.9 million in cash, cash equivalents, and short-term investments.

Day One shares rose 3.5% in premarket trading.

Price: 15.90, Change: +0.54, Percent Change: +3.52